Results
1 -
6 of
6Krisch I, Bole-Vunduk B, Pepelnak M, Lavric B, Ocvirk A, Budihna M V, Sket D.
Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841., The Journal of pharmacology and experimental therapeutics, Oct 1994 Zivin M, Sprah L, Sket D.
The D1 receptor-mediated effects of the ergoline derivative LEK-8829 in rats with unilateral 6-hydroxydopamine lesions., British journal of pharmacology, Nov 1996 Sprah L, Zivin M, Sket D.
Ergoline derivative LEK-8829-induced turning behavior in rats with unilateral striatal ibotenic acid lesions: interaction with bromocriptine., The Journal of pharmacology and experimental therapeutics, Mar 1999 Glavan Gordana, Sket Dusan, Zivin Marko.
Modulation of neuroleptic activity of 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate (LEK-8829) by D1 intrinsic activity in hemi-parkinsonian rats., Molecular pharmacology, Feb 2002 Zivin M, Sprah L, Sket D.
Antiparkinsonian potential of interaction of LEK-8829 with bromocriptine., European journal of pharmacology, May 1998 The dopamine D1 receptor agonist and D2 receptor antagonist LEK-8829 attenuates reinstatement of cocaine-seeking in rats, Naunyn-Schmiedeberg's Archives of Pharmacology